Roquefort Therapeutics PLC
ROQ
Company Profile
Business description
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. The product portfolio of the company consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical development of next-generation medicines focused on hard-to-treat cancers.
Contact
85 Great Portland Street
First Floor
LondonW1W 7LT
GBRT: +44 2039188633
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,162.80 | 13.70 | 0.15% |
| CAC 40 | 7,870.34 | 65.37 | 0.84% |
| DAX 40 | 24,377.50 | 191.91 | 0.79% |
| Dow JONES (US) | 44,911.26 | 11.01 | -0.02% |
| FTSE 100 | 9,177.24 | 12.01 | 0.13% |
| HKSE | 25,327.43 | 191.89 | -0.75% |
| NASDAQ | 21,710.67 | 2.47 | -0.01% |
| Nikkei 225 | 42,947.08 | 297.82 | 0.70% |
| NZX 50 Index | 12,880.68 | 46.60 | 0.36% |
| S&P 500 | 6,468.54 | 1.96 | 0.03% |
| S&P/ASX 200 | 8,886.40 | 12.60 | 0.14% |
| SSE Composite Index | 3,674.40 | 7.96 | 0.22% |